Publications by authors named "E Gherga"
Background: Chemoradiotherapy with high-dose cisplatin (HD-Cis: 100 mg/m q3w for three cycles) is the standard of care (SOC) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Cumulative delivered dose of cisplatin is prognostic of survival, even beyond 200 mg/m but high toxicity compromises its delivery.
Aim: Cisplatin fractionation may allow, by decreasing the peak serum concentration, to decrease toxicity.
Introduction: We report long-term efficacy and overall survival (OS) results from a randomised, double-blind, phase 2 study (NCT02022098) investigating xevinapant plus standard-of-care chemoradiotherapy (CRT) vs. placebo plus CRT in 96 patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
Methods: Patients were randomised 1:1 to xevinapant 200 mg/day (days 1-14 of a 21-day cycle for 3 cycles), or matched placebo, plus CRT (cisplatin 100 mg/m every 3 weeks for 3 cycles plus conventional fractionated high-dose intensity-modulated radiotherapy [70 Gy/35 F, 2 Gy/F, 5 days/week for 7 weeks]).
Purpose: To assess the efficacy and the tolerance of a split course hypofractionated (SCH) radiotherapy (RT) protocol in head and neck cancer (HNC) for eldery and/or unfit patients (pts).
Patients And Methods: Pts with HNC treated by SCH-RT in two institutions were included retrospectively. The main SCH RT regimen was two courses of 30 grays (Gy)/10 fractions separated by 2-4 weeks, without any systemic therapy.
Article Synopsis
- Debio 1143 is a novel oral drug that potentially boosts the effectiveness of cisplatin and radiotherapy in treating high-risk locally advanced squamous cell carcinoma of the head and neck by activating specific immune pathways.
- The study involved a randomized, double-blind design with participants receiving either Debio 1143 or a placebo alongside standard chemoradiotherapy across 19 hospitals in France and Switzerland.
- Researchers aimed to evaluate the safety and efficacy of the treatment, focusing on how many patients maintained locoregional control 18 months post-therapy, using established cancer response criteria.
Background: FOLFIRINOX regimen is the first-line reference chemotherapy (L1) in advanced pancreatic ductal adenocarcinoma (aPDAC). FOLFOXIRI, a schedule with a lower dose of irinotecan and no bolus 5-fluorouracil, has demonstrated efficacy and feasibility in colorectal cancer.
Aim: To investigate the potential clinical value of FOLFOXIRI in patients with aPDAC in routine clinical practice.